Repeated Low-Dose Administration of the Monoacylglycerol Lipase Inhibitor JZL184 Retains Cannabinoid Receptor Type 1–Mediated Antinociceptive and Gastroprotective Effects

The monoacylglycerol lipase (MAGL) inhibitor 4-nitrophenyl 4-(dibenzo[d][1,3]dioxol-5-yl(hydroxy)methyl)piperidine-1-carboxylate (JZL184) produces antinociceptive and anti-inflammatory effects. However, repeated administration of high-dose JZL184 (40 mg/kg) causes dependence, antinociceptive toleran...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Kinsey, Steven G., Wise, Laura E., Ramesh, Divya, Abdullah, Rehab, Selley, Dana E., Cravatt, Benjamin F., Lichtman, Aron H.
Format: Artigo
Sprache:Inglês
Veröffentlicht: The American Society for Pharmacology and Experimental Therapeutics 2013
Schlagworte:
Neuropharmacology
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC3657109/
https://ncbi.nlm.nih.gov/pubmed/23412396
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1124/jpet.112.201426
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge